Skip to main content

Table 2 Detailed cohort characteristics

From: The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

  All (n = 36) LD GM-CSF (n = 6) LD Alhydrogel (n = 6) MD GM-CSF (n = 6) MD Alhydrogel (n = 6) HD GM-CSF (n = 6) HD Alhydrogel (n = 6)
Age (years) 44.0 (38.5–49.7) 45.2 (39.7–50.5) 44.4 (35.8–54.5) 37.2 (27.8–46.9) 49.7 (45.7–50.8) 44.0 (41.5–46.0) 40.1 (38.0–45.3)
Time since diagnosis (years) 5.2 (3.1–9.8) 3.9 (2.2–6.3) 5.9 (3.0–7.29 4.1 (2.8–11.0) 6.4 (3.4–9.1) 5.9 (3.2–15.8) 9.8 (4.6–15.9)
Time on ART (years) 2.3 (1.4–3.9) 2.0 (1.4–2.8) 2.5 (1.7–2.6) 2.3 (1.3–2.7) 3.3 (1.9–4.8) 1.3 (1.1–1.5) 4.8 (2.0–7.4)
Nadir CD4 (cells/μl) 290 (234–360) (n = 35) 318 (230–475) 357 (268–366) 283 (269–295) (n = 5) 275 (234–343) 258 (228–380) 302 (219–340)
CD4 (cells/μl) 626 (529–758) 679 (580–1006) 656 (563–728) 610 (546–713) 529 (498–596) 654 (624–840) 706 (514–821)
CD8 (cells/μl) 1051 (794–1250) 1178 (798–2268) 1002 (764–1173) 921 (345–1256) 1104 (795–1308) 905 (658–1040) 1195 (932–1258)
HIV RNA (copies/ml) 0b (0 - <20) 0 (0 - <20) 0 (0–0) 0 (0 - <20) 0 (0 - <20) 0 (0–0) 0 (0 - <20)
PreART CD4 (cells/μl)a 341 (210–845) (n = 34) 358 (211–845) 360 (268–840) 295 (210–398) (n = 5) 301 (220–480) 306 (226–454) (n = 5) 370 (266–840)
PreART RNA (copies/ml)a 7.3 × 104 (1.7 102–7.3 105) (n = 35) 8.0 × 104 (1.2 104–1.0 105) 3.3 × 104 (1.7 102–7.2 105) 1.5 × 105 (2.6 104−3.4 105) (n = 5) 1.1 × 105 (7.3 104–4.3 105) 4.8 104 (1.7 104–3.0 105) 3.2 × 104 (2.3 103–7.3 105)
Anti-Vacc-C5 AB (ng/ml) 1433 (390–4678) 390 (390–1934) 1341 (390–2396) 723 (390–4894) 1394 (458–5282) 1239 (390–4401) 7309 (3280–9772)
  1. Median (interquartile range)
  2. aMedian (min-max)
  3. b0 implies undetectable PCR product